Literature DB >> 2578670

Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child.

R D Todd, R D Ciaranello.   

Abstract

Serotonin (5-HT) binding sites from bovine and rat cerebral cortex membranes share pharmacological properties that allow both to be subclassified by the same criteria. We show here that [3H]5-HT binding sites from human cortex also possess pharmacological properties that follow the same subclassification scheme as for bovine and rat cortex. In addition, we show that solubilized 5-HT1 and 5-HT3 sites from all three species have an s20,w value of 3.4. Despite these similar pharmacological and physical characteristics, we can demonstrate antigenic differences between receptor types and species. Human 5-HT1A sites can be distinguished from human 5-HT1B, 5-HT2, and 5-HT3 sites and from equivalent sites in rat and bovine cortex. The anti-human 5-HT1A antibodies were discovered in the blood of an autistic child and may have clinical or etiologic significance for this disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578670      PMCID: PMC397091          DOI: 10.1073/pnas.82.2.612

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  11 in total

1.  Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.

Authors:  R R Almon; C G Andrew; S H Appel
Journal:  Science       Date:  1974-10-04       Impact factor: 47.728

2.  Antibodies to the beta-adrenergic receptor: attenuation of catecholamine-sensitive adenylate cyclase and demonstration of postsynaptic receptor localization in brain.

Authors:  C D Strader; V M Pickel; T H Joh; M W Strohsacker; R G Shorr; R J Lefkowitz; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

3.  Structure of the yeast mitochondrial adenosine triphosphatase. Results of trypsin degradation.

Authors:  R D Todd; M G Douglas
Journal:  J Biol Chem       Date:  1981-07-10       Impact factor: 5.157

Review 4.  The syndrome of autism: a critical review.

Authors:  E M Ornitz; E R Ritvo
Journal:  Am J Psychiatry       Date:  1976-06       Impact factor: 18.112

5.  Use of monoclonal antibodies to study acetylcholine receptors from electric organs, muscle, and brain and the autoimmune response to receptor in myasthenia gravis.

Authors:  J Lindstrom; S Tzartos; W Gullick; S Hochschwender; L Swanson; P Sargent; M Jacob; M Montal
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1983

6.  Solubilization and characterization of high-affinity [3H]serotonin binding sites from bovine cortical membranes.

Authors:  S R VandenBerg; R L Allgren; R D Todd; R D Ciaranello
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

7.  High-affinity binding of (3H) 5-hydroxytryptamine to brain synaptosomal membranes: comparison with (3H) lysergic acid diethylamide binding.

Authors:  G M Fillion; J C Rousselle; M P Fillion; D M Beaudoin; M R Goiny; J M Deniau; J J Jacob
Journal:  Mol Pharmacol       Date:  1978-01       Impact factor: 4.436

8.  Two distinct serotonin receptors: regional variations in receptor binding in mammalian brain.

Authors:  S J Peroutka; S H Snyder
Journal:  Brain Res       Date:  1981-03-16       Impact factor: 3.252

9.  Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain.

Authors:  N W Pedigo; H I Yamamura; D L Nelson
Journal:  J Neurochem       Date:  1981-01       Impact factor: 5.372

10.  Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders.

Authors:  S M Stahl; D J Woo; I N Mefford; P A Berger; R D Ciaranello
Journal:  Am J Psychiatry       Date:  1983-01       Impact factor: 18.112

View more
  23 in total

1.  Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism.

Authors:  G DelGiudice-Asch; L Simon; J Schmeidler; C Cunningham-Rundles; E Hollander
Journal:  J Autism Dev Disord       Date:  1999-04

Review 2.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 3.  Is autism associated with anomalous dominance?

Authors:  M Leboyer; D N Osherson; M Nosten; P Roubertoux
Journal:  J Autism Dev Disord       Date:  1988-12

Review 4.  Etiology of infantile autism: a review of recent advances in genetic and neurobiological research.

Authors:  G Trottier; L Srivastava; C D Walker
Journal:  J Psychiatry Neurosci       Date:  1999-03       Impact factor: 6.186

5.  Allergic sensitization in infantile autism.

Authors:  B Bidet; M Leboyer; B Descours; M P Bouvard; J Benveniste
Journal:  J Autism Dev Disord       Date:  1993-06

6.  Clinical effects of fenfluramine in ten autistic subjects.

Authors:  W M Klykylo; D Feldis; D O'Grady; D L Ross; C Halloran
Journal:  J Autism Dev Disord       Date:  1985-12

7.  Purification and reconstitution of serotonin receptors from bovine brain.

Authors:  T K Gallaher; H H Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

8.  Brain opioids and autism: an updated analysis of possible linkages.

Authors:  T L Sahley; J Panksepp
Journal:  J Autism Dev Disord       Date:  1987-06

9.  Receptor inhibition by immunoglobulins: specific inhibition by autistic children, their relatives, and control subjects.

Authors:  E H Cook; B D Perry; G Dawson; M S Wainwright; B L Leventhal
Journal:  J Autism Dev Disord       Date:  1993-03

10.  Hyperserotoninemia and antiserotonin antibodies in autism and other disorders.

Authors:  A Yuwiler; J C Shih; C H Chen; E R Ritvo; G Hanna; G W Ellison; B H King
Journal:  J Autism Dev Disord       Date:  1992-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.